Eko Rianova Lynoora, NIM011180401 (2017) KADAR MALONDIALDEHYDE (MDA) PADA PASIEN KUSTA REAKSI DAN TANPA REAKSI. Thesis thesis, Universitas Airlangga.

Preview	Text (abstrak) abstrak.pdf Download (91kB) | Preview
	Text (full text) Karya Akhir_Eko Rianoma Lynoora NIM 011180401.compressed.pdf Restricted to Registered users only until 31 October 2020. Download (1MB)

Abstract

Leprosy reaction is an acute episodes that occurred in the chronic clinical process of leprosy. Leprosy reaction could make damage to the cells because of the oxidative stress process. Previous studies showed increasing oxidant levels in leprosy reaction patient. Malondialdehyde (MDA) is one of the biomarker of oxidative stress that plays important role in pathogenesis of leprosy and leprosy reaction. Purpose: To measure plasma levels of MDA in leprosy reaction patient and leprosy without reaction in Dermato Venereology outpatient clinic in Dr.Soetomo general hospital Surabaya. Methods: This study was a descriptive observational study, with 27 leprosy patients in Dermato Venereology outpatient clinic Dr.Soetomo general hospital and 27 age-sex matched controls (nonleprosy subjects) that qualify inclusion and exclusion criteria. Plasma MDA was measured in both groups using ELISA. Results: Mean plasma MDA in leprosy patient are 572,53 ± 333,04 ng/mL and 705,31 ± 187,23 ng/mL in control groups. Mean plasma MDA in leprosy patient without reaction are 632,26 ± 352,28 ng/mL, mean plasma MDA in leprosy patient with type 1 reaction are 479,6 ± 120,76 ng/mL, and mean plasma MDA in leprosy patient with type 2 reaction are 490,67 ± 69,33 ng/mL. Mean plasma MDA in paucibacillary leprosy patient are 318,26 ± 97,58 ng/mL, and mean plasma MDA in multibacillary leprosy patient are 630,31 ± 280,27 ng/mL. Conclusions: Mean plasma MDA in control groups is higher than leprosy patient, mean plasma MDA in leprosy without reaction is higher than leprosy reaction. There is a trend increasing of MDA toward lepromatous type, and need further research to reveal the role exogenous antioxidant in leprosy patient

Actions (login required)

View Item